Requirement for Rho in Integrin Signalling
Simon T. Barry(AstraZeneca (Singapore)), Anne J. Ridley(University of Bristol), Martin J. Humphries(Wellcome Centre for Cell-Matrix Research), Helen M. Flinn(Ludwig Cancer Research), David R. Critchley(University of Leicester)
Cited by 126
Related Papers
Integrin ligands at a glance
|Journal of Cell Science|2006|1.7k
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
|Cancer Research|2013|1.5k
Integrin Structure, Activation, and Interactions
|Cold Spring Harbor Perspectives in Biology|2011|1.2k
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
|Advanced Drug Delivery Reviews|2016|1.1k
Vinculin controls focal adhesion formation by direct interactions with talin and actin
|The Journal of Cell Biology|2007|916